184 related articles for article (PubMed ID: 32187475)
1. Screening and Treatment Program to Eliminate Hepatitis C in Egypt.
Waked I; Esmat G; Elsharkawy A; El-Serafy M; Abdel-Razek W; Ghalab R; Elshishiney G; Salah A; Abdel Megid S; Kabil K; El-Sayed MH; Dabbous H; El Shazly Y; Abo Sliman M; Abou Hashem K; Abdel Gawad S; El Nahas N; El Sobky A; El Sonbaty S; El Tabakh H; Emad E; Gemeah H; Hashem A; Hassany M; Hefnawy N; Hemida AN; Khadary A; Labib K; Mahmoud F; Mamoun S; Marei T; Mekky S; Meshref A; Othman A; Ragab O; Ramadan E; Rehan A; Saad T; Saeed R; Sharshar M; Shawky H; Shawky M; Shehata W; Soror H; Taha M; Talha M; Tealaab A; Zein M; Hashish A; Cordie A; Omar Y; Kamal E; Ammar I; AbdAlla M; El Akel W; Doss W; Zaid H
N Engl J Med; 2020 Mar; 382(12):1166-1174. PubMed ID: 32187475
[No Abstract] [Full Text] [Related]
2. MSF pushes down price of generic hepatitis C drugs to new low level.
Wise J
BMJ; 2017 Nov; 359():j5054. PubMed ID: 29092825
[No Abstract] [Full Text] [Related]
3. [Not Available].
Stingl W
MMW Fortschr Med; 2015 Jun; 157 Suppl 2():55. PubMed ID: 26048126
[No Abstract] [Full Text] [Related]
4. Universal Disease Screening and Treatment - The Egyptian Example.
Haseltine WA
N Engl J Med; 2020 Mar; 382(12):1081-1083. PubMed ID: 32187465
[No Abstract] [Full Text] [Related]
5. Therapy for hepatitis C genotype 3: moving forward.
Buti M; Llaneras J; Riveiro-Barciela M; Esteban R
J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir.
Chia XX; Cherepanoff S; Danta M; Furlong T
Nephrology (Carlton); 2018 Apr; 23(4):379-380. PubMed ID: 29520905
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Saint-Laurent Thibault C; Moorjaney D; Ganz ML; Sill B; Hede S; Yuan Y; Gorsh B
J Med Econ; 2017 Jul; 20(7):692-702. PubMed ID: 28294645
[TBL] [Abstract][Full Text] [Related]
8. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
10. [Hepatitis C in Egypt, a iatrogenic epidemic].
Vrolijk JM; Schalm SW
Ned Tijdschr Geneeskd; 2000 Dec; 144(49):2378. PubMed ID: 11129975
[No Abstract] [Full Text] [Related]
11. HCV in Egypt, prevention, treatment and key barriers to elimination.
El Kassas M; Elbaz T; Elsharkawy A; Omar H; Esmat G
Expert Rev Anti Infect Ther; 2018 Apr; 16(4):345-350. PubMed ID: 29506418
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
[TBL] [Abstract][Full Text] [Related]
13. Real-Life Efficacy of 5 Different Antiviral Regimens for Treatment of Chronic Hepatitis C With Normal Liver Enzymes.
El Kassas M; Alboraie M; Elsaeed K; Ahmed Y; El Tahan A; Alhaddad O; Salaheldin M; Kabbash I; El Badry M; Fathy T; El-Serafy M; ElShazly Y; Doss W; Esmat G
Am J Ther; 2018; 25(6):e776-e779. PubMed ID: 30124480
[No Abstract] [Full Text] [Related]
14. [Effectiveness and safety of sofosbuvir+daclatasvir in the treatment of chronic hepatitis C virus infection in Yan'an, Shaanxi].
Gao XH; Jing P
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):457-459. PubMed ID: 31357763
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
Restelli U; Alberti A; Lazzarin A; Bonfanti M; Nappi C; Croce D
Eur J Health Econ; 2018 Jan; 19(1):37-44. PubMed ID: 28008546
[TBL] [Abstract][Full Text] [Related]
16. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
Perazzo H; Jorge MJ; Silva JC; Avellar AM; Silva PS; Romero C; Veloso VG; Mujica-Mota R; Anderson R; Hyde C; Castro R
BMC Gastroenterol; 2017 Nov; 17(1):119. PubMed ID: 29169329
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
Eckman MH; Ward JW; Sherman KE
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
[TBL] [Abstract][Full Text] [Related]
18. What does it mean to put new hepatitis C drugs on a list of essential medicines?
Urrutia J; Porteny T; Daniels N
BMJ; 2016 Apr; 353():i2035. PubMed ID: 27106956
[No Abstract] [Full Text] [Related]
19. Indian hepatitis C drug patent decision shakes public health community.
't Hoen EFM
Lancet; 2016 Jun; 387(10035):2272-2273. PubMed ID: 27238944
[No Abstract] [Full Text] [Related]
20. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.
McEwan P; Bennett H; Ward T; Webster S; Gordon J; Kalsekar A; Yuan Y; Brenner M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):173-80. PubMed ID: 26545086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]